GlaxoSmithKline To Market Merck’s Mevacor OTC In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
An FDA joint advisory committee meets Dec. 13 to evaluate Merck data supporting the Rx-to-OTC switch.
You may also be interested in...
FDA Advisors Again Deny Lovastatin OTC Status
Merck fails in third attempt to convince panel consumers can make an appropriate self-selection decision regarding Mevacor Daily.
FDA Advisors Again Deny Lovastatin OTC Status
Merck fails in third attempt to convince panel consumers can make an appropriate self-selection decision regarding Mevacor Daily.
Third's A Charm? Merck Again Faces FDA Panel To Request Mevacor Switch To OTC
FDA’s Nonprescription Drugs and Endocrinologic and Metabolic Drugs committees to review Mevacor Rx-to-OTC switch proposal Dec. 13.